Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Enrollment opens in phase III VICTORIA study of vericiguat for HFrEF

Sep. 28, 2016

Inotrem completes phase I study of Motrem

Sep. 16, 2016

FDA approves Aralez Pharmaceuticals' Yosprala

Sep. 16, 2016

New gene silencing model confirms the XPO1 gene as a target for treating heart failure

Sep. 15, 2016

MicroRNA 132 can be targeted to improve pressure-induced heart failure

Sep. 14, 2016

FDA clears Angionetics' phase III study of Generx gene therapy

Sep. 13, 2016

Takeda Pharmaceutical presents new renin inhibitor

Sep. 12, 2016

Phase IIIb trials to study use of dapagliflozin for chronic kidney disease and chronic heart failure

Sep. 12, 2016

Bristol-Myers Squibb, Universite de Montreal patent novel PAR4 antagonists

Sep. 9, 2016

Theravance Biopharma presents new neprilysin inhibitors

Sep. 8, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.